Novocure Reports First Quarter 2024 Financial Results
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
Novocure Announces Last Patient Enrolled in Ph 3 TRIDENT Trial in Glioblastoma
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues